Jacqueline Nusselder

Under-mortality among COVID-19 vaccinated and excess mortality among unvaccinated people  "In 2021 and 2022, there was considerable excess mortality among people in the general population without COVID-19 vaccination. This is shown by research by Nivel. On the other hand, there was undermortality among vaccinated people. In the group of unvaccinated people, COVID-19 was twice as often the cause of death in both men and women as in vaccinated men and women. In the group of people with a COVID-19 vaccination, fewer deaths than expected occurred in the first 3 and first 12 months after the first vaccination. There were up to 45% fewer deaths than expected based on data on population characteristics and deaths for 2015 to 2018. This could be related to the COVID-19 measures. The researchers see the effects of this in society on several fronts: for example, there was no flu epidemic in 2021 and it started later in 2022; There were fewer other infectious diseases and the number of (fatal) traffic accidents was also lower than in previous years. COVID-19 vaccination has prevented many deaths, especially in vulnerable groups, such as people with diabetes, people with COPD and people with cardiovascular diseases, but also the oldest elderly (81 years and older)." https://lnkd.in/ekywKFnu

4

🗞️ Another EMA-endorsed Study from VAC4EU - Vaccine Monitoring Collaboration for Europe! 🗞️ We’re excited to share that the latest post-authorisation safety study (PASS) protocol from the VAC4EU - Vaccine Monitoring Collaboration for Europe network, focused on monitoring Pfizer-BioNTech’s COVID-19 booster vaccine, has been officially approved by the EMA! ✅ The #VAC4EU network, with Teamit Institute playing an active role as study managers, will oversee this important study over the next two years. The aim? To provide deeper insights into the safety of COVID-19 booster vaccines across Europe. 🌍 Stay updated on this and other post-marketing surveillance studies by following VAC4EU - Vaccine Monitoring Collaboration for Europe and learn more about Teamit Institute’s role here ➡️ [https://chloom.ly/b0cVLxw] 🔍 Read the full PASS protocol here ➡️ [https://loom.ly/hbyIdKw] VAC4EU - Vaccine Monitoring Collaboration for Europe member organisations involved: UMC Utrecht, RTI Health Solutions, Teamit , Penta Foundation - Child Health Research, Società Servizi Telematici S.r.l. (PEDIANET), PHARMO Institute, part of Lumanity, University of Oslo, Instituto Aragonés de Ciencias de la Salud (IACS), Drug Safety Research Unit (DSRU) and IDIAPJGol. #VAC4EU #COVID19 #Pharmacoepidemiology #TeamitImpact

16

deze ziekte wordt vaak verspreid in het westelijke kustgebied van Jemen. persoonlijk heb ik verschillende gevallen gediagnosticeerd volgens de conventionele technieken van vóór 2015. Onder de Artikel samenvatten (NVMM 2024) Onchocerciasis is a rare parasitic traveler's infection and is caused by a threadworm (Onchocerca volvulus), particularly in Central Africa. Severe itching, localized swelling (onchocercoma) and finally blindness may occur. In this case report, a subcutaneous swelling is removed in an otherwise healthy woman, which in the pathology laboratory turns out to be an onchocercoma. The patient is treated with doxycycline and ivermectin for onchocerciasis. Presentation with onchocerciasis is extremely rare in the Netherlands. Perform diagnostics for onchocerciasis in patients who had prolonged stays in Central-Africa or Yemen and present with local swelling, severe itching or progressive vision complaints. Treatment comprises doxycycline and ivermectin.

2

On 8 April, the Dutch Minister of Medical Care sent a letter to Dutch Parliament regarding interactions between life sciences companies and health care professionals. In this article, we analyze the measures as proposed by the Minister of Medical Care, when the measures are expected to come into force and the key take-aways of the letter of the Minister. #healthcare #lifesciences Hein van den Bos, Julia Mischie

2

New Dutch translation: Competency Framework for Adult Endocrine Nursing 👉 https://lnkd.in/ezmWfBUC The Competency Framework for Adult Endocrine Nursing was developed by a working group of UK Endocrine Specialist Nurses and the Society for Endocrinology (SfE) to enhance the clinical care that adults with an endocrine disorder receive. The Competency Framework focuses on the knowledge, skills and interventions relevant to nurses looking after adult patients with endocrine conditions. It is envisaged that this document will be a useful tool for endocrine nurses across Europe and globally: ✔️ Supporting job descriptions and pay reviews/negotiations by detailing targets in accordance with local and national guidelines and policies ✔️ Assessing clinical competence at different levels ✔️ Developing personal goals and objectives in performance appraisals for career progression ✔️ Achieving a unified and translational role for endocrine nurses at a European and international level Please note, while the Competency Framework encompasses most functions included in the role of an endocrine nurse, it is not an accredited document outside the UK. It is only intended as guidance to role performance and should be used in conjunction with local and national guidelines and appraisal documents. #endocrinology #nursing

11

🌐 Beneluxa Webinar on Alzheimer’s Disease: Exploring New Horizons in Treatment On 6th June 2024, the Beneluxa Initiative held a #Beneluxa scoping webinar on #Alzheimer's disease. 30 experts, representing prescribers, public payers and patient organizations, of the five Beneluxa countries joined to discuss the evolving landscape of Alzheimer's treatment and to share their views on the potential benefits of the new medicines and implications for the organisation of care. The webinar hosted by the Dutch National Health Care Institute (Zorginstituut Nederland) marks a significant step in fostering international #collaboration and understanding the potential impacts of new treatments. 👉 More information: https://lnkd.in/dc7GehEa

42

We proudly present the 7️⃣th of 8️⃣ FIGHT KIDS CANCER research projects 👩‍🔬 🔬 🧑‍🔬. Because brain tumours 🧠 are among the deadliest paediatric cancer types, we will be exclusively allocating the RUN TO KICK 2024 funds 💸 to projects on these tumours. Ready🏎️❓The EUROPE will focus on finding new cures for paediatric Ependymoma Ependymoma is the third most common cancerous brain 🧠 tumor in children and adolescents. Current treatment mainly involves brain surgery 👨‍⚕️ and radiation, as standard chemotherapy is often ineffective. Even if patients are cured, these treatments can cause serious, long-lasting side effects . The EUROPE project aims to find new cures by studying tumor cells 🧫 that survive initial therapy and cause recurrences. Researchers will analyze cell communication within tumors, how normal cells affect tumor growth, and test the impact of current treatments in mouse models 🐁. They will also identify and test new drug 💊 candidates targeting resistant cells, including some not yet available on the market. Follow this link 🔗 to find out all details about this project: https://lnkd.in/duaU9MMt 👂 Stay tuned 👀 for more details on the other FIGHT KIDS CANCER research projects. Imagine for Margo - Children without Cancer | CRIS Cancer Foundation | CRIS contra el Cáncer | Stichting Kinderen Kankervrij (KiKa) 🙏 NRJ Belgium | Delhaize Belgium | The National Lottery #KickCancer #RUNTOKICK #CureDontCry #FightKidsCancer #ChildhoodCancer #PediatricCancer #KidsCancer #BrainTumourResearch #BrainTumorAwareness #Research #Innovation #CancerResearch #dipg #diffuseintrinsicpontineglioma #CancerResearch #RunningBE #Brussels

36

Kom erachter hoe goed jouw algehele performance is! Doe de FreeChoice Performance-check: https://lnkd.in/e2hEh2Vw #gezondheid #health #vitamine #performance

8

Key Insights From The Cancer Medicines Forum Workshop - EORTC - European Organisation for Research and Treatment of Cancer European Medicines Agency Belgian Presidency of the Council of the European Union 2024 #Amsterdam #AnticancerMedicines #Cancer #ClinicalResearch #EORTC #OncoDaily #Oncology #ResearchCollaboration

16

We are launching a targeted attack on prostate cancer! My company, CimCure B.V., in collaboration with SwiftPharma (Ghent, Belgium) and Amsterdam UMC, has secured a €1.1 million EU Eurostars project to develop a multi-targeted vaccination-based immunotherapy for prostate cancer. The project, titled "A sustainable first-in-class multi-targeted immunotherapy for the treatment of prostate cancer," will utilize an innovative production method using tobacco plants (Nicotiana benthamiana, see image below). This sustainable “green” approach eliminates the need for bioreactors, culture media, electricity, maintenance instruments and chemicals, relying solely on soil and sunlight. With this project, we are pioneering a path towards sustainable and accessible therapy for all cancer patients.   Jeroen Hofenk Diederik Engbersen Elisabeth (Else) Huijbers Karlijn van Loon Judy van Beijnum Health & Innovation District Amsterdam (Hid) Amsterdam UMC - Cancer Center Amsterdam CimCure B.V. #Cancer #Vaccines #Immunotherapy #Conference #Research #Healthcare #Innovation #Amsterdam

177

22 commentaren

Discover this publication on guideline-directed medical therapy for heart failure, published in Acta Cardiologica and available as open access on Taylor & Francis Online. AstraZeneca was the funding source and was involved in all stages of the survey conduct and analysis.   The "Delphi Panel"—consisting of 12 Belgian heart failure specialists—achieved consensus on how to integrate GDMT in clinical practice, considering the local healthcare landscape and reimbursement criteria. This national consensus provides a practical roadmap for cardiologists and other healthcare providers to elevate heart failure care across Belgium.   🔗  https://lnkd.in/gd3hnPpu   With this work, we believe this will drive impactful change and improve patient outcomes by bridging the gap between guidelines and real-world practice.   AZ BeLux, From hope, to impact.   #FromHopeToImpact #HeartFailure #GDMT #HFrEF #Cardiology #ESCguidelines #HealthcareInnovation #Belgium #MedicalResearch #ActaCardiologica Joke Devoldere Anke Van den broeck Ward A. Heggermont Steven Droogmans Emeline Van Craenenbroeck

3

1 commentaar

https://lnkd.in/eCcDRrCq Financial conflicts of interest (FCOI) of medical professionals and associated organizations with pharmaceutical companies (pharma) potentially contribute to the use of low value oncological treatments. In the Netherlands more than half of cancer patient advocacy organizations (cPAOs) receive sponsoring by pharma as reported on their websites, in available annual reports and in the Dutch Healthcare Transparency Registry. In 29.4% of cPAOs no reporting of pharma sponsoring could be found.  Given the importance of cPAOs for patient care including family support, provision of information and the importance of their objective input in the societal debate on the availability and use of cancer drugs, the potential influence of pharma sponsoring should be critically evaluated. https://lnkd.in/eBhu7Cap

22

The final report of the IBD Hackathon Maastricht has been presented to Bianca Rouwenhorst from the Ministry of Health, Welfare, and Sport. The report contains important conclusions and recommendations for further development of the healthcare information system. The full report is now available: https://lnkd.in/e6wtVbJA. #healthdata #openEHR #HL7FHIR #OMOP #datahub #datahubmaastricht

9

During the recently concluded American Academy of Neurology Annual Meeting (2024), Biohaven presented abstracts detailing the characterization of their lead candidate within the Kv7 platform, BHV-7000, as a potential treatment for seizures. These abstracts highlighted BHV-7000's pharmacodynamic impact on electroencephalogram (EEG) spectral power in healthy adults, as well as the safety and tolerability of both single and multiple ascending doses (SAD and MAD) of oral BHV-7000. BHV-7000, a clinically validated target in epilepsy, has exhibited potent anti-seizure properties in the maximal electroshock seizure model, with no discernible adverse effects on neurobehavioral functioning or motor abilities. Explore more about the Epilepsy treatment market @ https://lnkd.in/gwagSPYZ #AAN2024 #Biohaven #BHV7000 #Kv7Platform #SeizureTreatment #Epilepsy #NeurologyConference

12

ERDERA opens a new era for rare disease research in Europe and beyond! 🚀   👩🏽‍🔬​Backed by the European Union, over 170 organizations are uniting to make Europe a leader in rare disease research and innovation. Amsterdam UMC, we're proud to partner with the European Rare Disease Research Alliance (ERDERA) that builds up among others on the achievements made in ERICA! 🌍💙   Read ERDERA’s press release to learn more 🗞️https://bit.ly/3zgaZA0   🌐 erdera.org #ERDERA #RareDiseases #ResearchInnovation #HealthInnovation   A game-changing partnership, championed by the European Union and member states 🎯   ERDERA brings together over 170 organizations from 37 countries representing the public and private sectors to make Europe a world leader in rare disease research and innovation.   With an overall estimated budget of 380 million euros, ERDERA is set to boost game-changing research, expediting the translation of the most promising results into socio-economic benefits for patients and healthcare systems, whilst fostering international and national alignment and collaboration.

16

One of the quickest ways to create patient impact applying AI in pharmacology

6

🎯 Involving patients in the decision-making regarding disease management is crucial. Patients should be informed about various options, their advantages and disadvantages, and allowed to make decisions. Professor Wytske Fokkens advocates for #patients making their own decisions, but having access to necessary information is essential for making informed choices, which remains a significant challenge. The goal is to empower patients by giving them a sense of control over their healthcare journey. By ensuring they have access to all necessary information and support, we can pave the way for more personalised and effective treatment plans that align with the patient's values and lifestyle. Listen to Prof. Wytske Fokkens on Patient Decision-Making and Patient Empowerment: https://lnkd.in/erMB8gB8 📽 This interview was recorded during the Global CRSwNP Awareness Day in Brussels, April 2024, and it is an educational product of EUFOREA! Visit our website for more information about the 2024 CRSwNP Awareness Day initiative: https://lnkd.in/dd-2p6u9 #NasalPolypSyndrome #ngo #brussels #advocacy #asthma #ChronicRespiratoryDisease #PatientCare #RespiratoryCare #ChronicRhinosinusitis #NasalPolyps #GlobalAwarenessDay #EUFOREA #PatientEmpowerment #HealthcareAdvocacy #TogetherWeCanMakeADifference

6

Why would you share your wearable data with your healthcare professional? 🎬 Discover the answers in this series of 20+ videos. This one is about the ANNUAL CHECK-UP.

9

1 commentaar

𝗛𝗼𝘄 𝘁𝗼 𝗮𝗰𝗵𝗶𝗲𝘃𝗲 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝘃𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗨.𝗦. 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗺𝗮𝗿𝗸𝗲𝘁 LIOF, Brightlands Maastricht Health Campus and RQR Advisors LLC are organizing an exclusive two-day workshop to prepare medical companies for the U.S. market. The U.S. market is attractive to European manufacturers of medical products due to its extensive healthcare expenditure and strong demand for advanced products and technologies. Due to the challenges on the European MDR-regulations, more and more medical companies consider going to the U.S. market parallel to or even before the EU market.

1